Press Releases

Date	Title and Summary	View
Toggle Summary May 15, 2018	Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update Completion of follow on offering netting $45.7 million Issuance of new US patent Long-term safety study now has 250 subjects enrolled FREMONT, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company	View HTML Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update 89.4 KB
Toggle Summary May 14, 2018	Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study 250 subjects have enrolled in the Study The Study is set to complete enrollment on May 18th FREMONT, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical stage biopharmaceutical company focused on providing rapid systemic administration	View HTML Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study 20.6 KB
Toggle Summary May 08, 2018	Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update FREMONT, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray	View HTML Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update 14.8 KB
Toggle Summary Apr 03, 2018	Zosano Announces Closing of Public Offering of Common Stock FREMONT, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the closing of the previously	View HTML Zosano Announces Closing of Public Offering of Common Stock 16.6 KB
Toggle Summary Apr 02, 2018	Zosano Pharma to Host Conference Call to Provide Operational Update FREMONT, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today	View HTML Zosano Pharma to Host Conference Call to Provide Operational Update 15.4 KB
Toggle Summary Mar 29, 2018	Zosano Announces Pricing of Public Offering of Common Stock FREMONT, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the pricing of an	View HTML Zosano Announces Pricing of Public Offering of Common Stock 16.4 KB
Toggle Summary Mar 16, 2018	Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study 103 patients have enrolled in study	View HTML Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study 20.9 KB
Toggle Summary Mar 12, 2018	Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update First patient enrolled in long term safety study in November 2017 Pivotal efficacy data for M207 published in October 2017 Allowed patent application to be issued in March 2018 extends proprietary position for M207 to 2037 FREMONT, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma	View HTML Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update 89.5 KB
Toggle Summary Mar 02, 2018	Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine Patent extends proprietary position of M207 to 2037	View HTML Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine 17.6 KB
Toggle Summary Jan 25, 2018	Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on January 26, 2018	View HTML Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split 20.3 KB